LETTER TO THE EDITOR

Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework

Syed H. S. Naqvi 1, Martin J. Citardi 1, Davide Cattano 2, Luis Ostrosky-Zeichner 3, Mark I. Knackstedt 1 and Ron J. Karni 1*

Abstract

**Background:** The COVID-19 pandemic has raised concerns of inadvertent SARS-CoV-2 transmission to healthcare workers during routine procedures of the aerodigestive tract in asymptomatic COVID-19 patients. Current efforts to mitigate this risk focus on Personal Protective Equipment, including high-efficiency filtration as well as other measures. Because the reservoir for SARS-CoV-2 shedding is in the nasopharynx and nasal and oral cavities, the application of viricidal agents to these surfaces may reduce virus burden. Numerous studies have confirmed that povidone-iodine inactivates many common respiratory viruses, including SARS-CoV-1. Povidone-iodine also has good profile for mucosal tolerance. Thus, we propose a prophylactic treatment protocol for the application of topical povidone-iodine to the upper aerodigestive tract.

**Conclusion:** Such an approach represents a low-cost, low-morbidity measure that may reduce the risks associated with aerosol-generating procedures performed commonly in otolaryngology operating rooms.

**Keywords:** Povidone-iodine, Betadine, SARS-CoV-2, Prophylaxis, COVID-19, Upper Aerodigestive tract

Background

The COVID-19 pandemic has increased awareness of operating room transmission risks of the responsible virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 can remain aerosolized for at least three hours under experimental conditions and may persist for greater than 72 h on plastic and stainless steel surfaces; this creates substantial risks to all healthcare professionals [1]. The virus may reside in high concentrations in the nasal cavity, nasopharynx, oral cavity and oropharynx, and thus opportunities for dissemination of SARS-CoV-2 in the operating suite have been hypothesized [2, 3]. Intubation, as well as transoral and transnasal procedures, may pose a unique risk as viral particles may be aerosolized while performing these measures and contact with mucosa can be extensive. Various anecdotes confirm a relatively high prevalence of COVID-19 among otolaryngologists, and for this reason, special precautions have been proposed for many aerosol-generating transnasal procedures [4]. Given that a minority of infected patients may remain asymptomatic and that rapid and reliable screening remains limited, prevention against viral exposure has primarily focused on Personal Protective Equipment (PPE) [5–7]. Topical oronasal treatment with povidone-iodine (PVP-I), better known as Betadine™ (Avrio Health, LP), may be an effective method to immediately reduce the viral load of the upper aerodigestive tract and thus decrease the risk of inadvertent virus transmission.
Currently, there are no recommendation for routine anti-viral prophylaxis using PVP-I, despite a strong record of extensive viricidal activity. It is our contention that oronasal application of PVP-I may serve as a prophylaxis measure, alongside PPE, during invasive procedures involving the mucosa of the upper aerodigestive tract in the era of SARS-CoV-2 pandemic.

Mechanism of action

PVP-I functions as an antiseptic through several mechanisms and is considered to have the broadest spectrum of action compared to other common antiseptics such as chlorhexidine [8, 9]. The two most potent antiseptic metabolites of PVP-I are molecular I2 and hypoiodous acid, which deliver free iodine. These free iodine molecules oxidize amino acids, nucleic acids and cell membranes [10]. Through oxidation of cell surface receptors, PVP-I prevents the attachment of viruses to cellular receptors [11].

In vitro data

In 2006, Kawira et al. demonstrated inactivation of SARS-CoV-1 with various PVP-I dilutions from 0.23 to 1% at 2-min exposure time. In his discussion, Kawira writes: “PVP-I products for gargling and spraying the throat may have a prophylactic effect on SARS during outbreaks.” [12] In 2015, Eggers et al. reported that a 1% PVP-I gargle for 15 s reduced Middle East respiratory syndrome-related coronavirus (MERS-CoV) titer by greater than 99.99% [13]. In 2018, Eggers again demonstrated that both Severe Acute Respiratory Syndrome Coronavirus 1 (SARS-CoV-1) and MERS-CoV could be rapidly inactivated by PVP-I in concentrations as low as 0.23% applied for 15 s [14]. Other authors have reported similar viricidal effects on influenza, rotavirus, Ebola, HIV, adenovirus, polyomavirus, and hepatitis A [15–17]. Of note, PVP-I also has bactericidal effects against common oral pathogens such as Klebsiella pneumonia and Streptococcus pneumonia [9, 15, 18].

In vivo studies

To our knowledge, there are no in vivo studies of oronasal application of PVP-I to reduce coronavirus infection. A Japanese randomized control trial of daily PVP-I gargle versus a control group showed an improvement to incidence rate of first upper respiratory tract infection [19]. A subsequent cost-effectiveness study of daily prophylactic PVP-I gargling suggests that this is an acceptable strategy when looking at quality of life days and cost [20].

Nagatake et al. reported a 50% reduction in Pseudomonas aeruginosa, Staphylococcus aureus and Hemophilus influenza in 23 adults with chronic respiratory conditions by PVP-I gargling four times daily [21]. Shiraiishi et al. reported a significant decrease in absence rate due to common cold and influenza in a middle school where the use of PVP-I gargle was encouraged. In this same study, PVP-I gargle was associated with a mean reduction rate of bacterial count by 99.4% [22].

Ogata et al. compared bacterial levels in the oropharynx at intubation and at the tip of the endotracheal tube after extubating, among patients using PVP-I gargle or tap water gargle. The bacterial levels in the oropharynx at intubation were markedly lower in the PVP-I gargle group. Tap water gargle patients had higher levels of bacterial colonization of the endotracheal tube tip (26.1% of tap water gargle patients versus none in the PVP-I gargle group for level 3 or 4 bacterial colonization) [23].

Safety

Oral PVP-I gargle formulations are currently available as over-the-counter medications in many countries, including Japan and Canada. Rare cases of aspiration pneumonitis as well as thyroid dysfunction have been reported as side effects to povidone-iodine [24–27]. Cases of anaphylaxis, contact dermatitis and edema after exposure have also been reported [28–30]. Ingestion in high concentrations or quantities may lead to acute kidney injury and/or liver toxicity [31, 32]. PVP-I in low concentrations has not been known to stain teeth [33]. Topical oro-nasal PVP-I prophylaxis should not be considered in patients with iodine allergy or those undergoing radioiodine treatment. In a study of PVP-I oral gargle for cancer-associated oral mucositis, no mucosal irritation was reported [30, 34]. Of note, studies have shown that PVP-I is ciliotoxic in concentrations of 5% and 10% [35, 36].

Proposed prophylactic treatment

Prior to the induction of anesthesia, each patient self-administers PVP-I as follows:

- 15 ml 1% PVP-I as a swish and spit for 30 s

The protocol recommendation above could potentially also be applied in a clinic setting, where aerosol generating procedures are frequently performed. After general anesthesia has been induced,

- 1% PVP-I solution is applied to oral cavity, oropharynx, hypopharynx and laryngopharynx surfaces (for all transoral procedures or other procedures that cross these mucosal surfaces)
- 10–20 ml 1% PVP-solution is placed into the nasal cavity (for any transnasal procedure).
- Mucosal contact of the PVP-I solution is maintained for 30 s.
The rationale for using 1% PVP-I solution and 30 s mucosal contact time was determined on the basis of widespread over the counter availability and recommended instructions on usage of 1% PVP-I gargle and mouthwash in countries around the world [22].

Conclusion
PVP-I has been used for more than 60 years as a topical antiseptic agent. Of note, PVP-I is viricidal against a wide range of viruses, including coronaviruses. Numerous reports confirm that low doses of PVP-I applied for short periods of time are extremely effective at reducing viral load. The safety profile of topical application of PVP-I to oral mucosa has been demonstrated. As healthcare settings develop new protocols around SARS-CoV-2 prophylaxis, the application of PVP-I solutions to the upper aerodigestive tract appears to be a low-cost and simple intervention for reducing viral burden from relevant mucosal surfaces.

Mucosal PVP-I application, deployed alongside existing protocols for PPE, may decrease the risk of contamination to healthcare personnel, especially in procedures which traverse mucosal membranes of the head and neck. Additional studies to examine the quantitative effect of PVP-I on viral load, the duration of effect, and the safety of oronasal application of PVP-I are warranted. Strong consideration for institution of this prototype should be given in light of the risks of inadvertent SARS-CoV-2 transmission during aerosol-generating procedures of the upper aerodigestive tract.

Abbreviations
SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; PPE: Personal Protective Equipment; PVP-I: Povidone-iodine

Acknowledgements
Not applicable.

Authors’ contributions
SHSN was responsible for drafting the manuscript, acquisition and interpretation of data, analysis and final approval of the version to be published. MJF was responsible for proof reading and editing the manuscript, analysis, and final approval of the version to be published. DC was responsible for proof reading and editing the manuscript, analysis and final approval of the version to be published. MK was responsible for drafting, proof reading and editing the manuscript, analysis and final approval of the version to be published. RJK was responsible for proof reading and editing the manuscript, analysis and final approval of the version to be published.

Funding
None.

Availability of data and materials
Not applicable. Corresponding author available to answer unresolved questions upon request.

Ethics approval and consent to participate
This manuscript is exempt from The University of Texas Health Science Center at Houston institutional review board.

Consent for publication
Not applicable.

Competing interests
MUC serves as a consultant for Acclarent (Irvine, CA), BioMed ENT (San Antonio, TX), Medical Metrics (Houston, TX) and Stryker (Kalamazoo, MI). RJK serves as a consultant for Tactile Medical (Minneapolis, MN) and Medtronic (Boulder, CO).

Author details
1Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin Street, MSB 5.036, Houston, TX 77030, USA. 2Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. 3Department of Infectious Diseases, Department of Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

Received: 26 July 2020 Accepted: 13 October 2020

Published online: 27 October 2020

References
1. Van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–72.
2. Chen WJ, Yang JY, Lin JH, Fann CS, Osyetrov V, King CC, et al. Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms. Clin Infect Dis. 2006;42(11):1561–9.
3. Wong J, Goh QY, Tan Z, Lie SA, Tay YC, Ng SY, et al. Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore. Can J Anesth/J canadien d’anesthésie. 2020;67:732–45.
4. Patel ZM, Fernandez-Miranda J, Hwang PH, Nayak JV, Dodd R, Sajjadi H, et al. Letter: precautions for endoscopic Transnasal Skull Base surgery during the COVID-19 pandemic. Neurosurgery. 2020;87:E66–7.
5. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). Treasure Island: StatPearls; 2020.
6. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis campaign: guidelines on the Management of Critically ill Adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020.
7. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323:1406–7.
8. Lachapelle JM, Castel O, Casado AF, Leroy B, Micali G, Tennstedt D, Lambert J. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clinical Practice. 2013;10(5):579-92.
9. Yoneyama A, Shimizu M, Tabata M, Yashiro J, Takata T, Hikida M. In vitro short-time killing activity of povidone-iodine (Isodine gargle) in the presence of oral organic matter. Dermatol. 2006;212(1):103-8.
10. Kanagalingam J, Feliciano R, Hah JH, Libb H, Le TA, Lin JC. Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections. Int J Clin Pract. 2015;69(11):1247–56.
11. Srivilajjaroen N, Wilairat P, Hiramatsu H, Takahashi T, Suzuki T, Ito M, et al. Mechanisms of the action of povidone-iodine against human and avian influenza viruses: its effects on hemagglutination and sialidase activities. Virol J. 2009;6:124.
12. Karwa H, Fuji N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatol. 2006;212(Suppl 1):119–23.
13. Eggers M, Eckmann M, Zorn J. Rapid and effective virucidal activity of Povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified Vaccinia virus Ankara (MVA). Infect Optim Ther. 2015;4(4):491–501.
14. Eggers M, Koburger-Janssens T, Eckmann M, Zorn J. In vitro bactericidal and virucidal efficacy of Povidone-iodine gargle/mouthwash against respiratory and Oral tract pathogens. Infect Dis Ther. 2018(7):249–59.
15. Eggers M. Infectious disease management and control with Povidone Iodine. Infect Dis Ther. 2019;8(4):581–93.
16. Harbison MA, Hammer SM. Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine. J Acquir Immune Defic Syndr (1988). 1989;2(1):16–20.
17. Kawana R, Kitamura T, Nakagomi O, Matsumoto J, Arita M, Yoshitani N, et al. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatol. 1997;195(Suppl 1):29–35.
18. Tsuda S, Soutome S, Hayashi S, Furushima M, Yamamoto S, Umeda M. Topical povidone iodine inhibits bacterial growth in the oral cavity of patients on mechanical ventilation: a randomized controlled study. BMC Oral Health. 2020;20(1):62.
19. Sato M, Shimo S, Omata K, Takahashi Y, Satomura K, Kitamura T, et al. Cost-effectiveness of gargling for the prevention of upper respiratory tract infections. BMC Health Serv Res. 2008;8:258.
20. Nagatate T, Ahmed K, Oishi K. Prevention of respiratory infections by povidone-iodine gargle. Dermatology. 2002;204(Suppl 1):32–6.
21. Shiraishi T, Nakagawa Y. Evaluation of the bactericidal activity of povidone-iodine and commercially available gargle preparations. Dermatology. 2002;204(Suppl 1):37–41.
22. Ogata J, Minami K, Miyamoto H, Horishita T, Ogawa M, Sata T, et al. Gargling with povidone-iodine reduces the transport of bacteria during oral intubation. Can J Anaesth. 2004;51(9):932–6.
23. Chepla KJ, Gosain AK. Intestinal pneumonitis due to Povidone-iodine aspiration during a facial bone fracture reduction operation. J Craniofac Surg. 2014;25(2):e172–e4.
24. Lithgow K, Symonds C. Severe thyrotoxicosis secondary to Povidone-iodine from peritoneal dialysis. Case Rep Endocrinol. 2017;2017:683126.
25. Kim CS, Kim SS, Bae EH, Ma SK, Kim SW, Mubarak M. Acute kidney injury due to povidone-iodine ingestion. Medicine. 2017;96(48):e8879.
26. Mao YC, Tsai WL, Wu ML, Ger J, Deng JF, Yang CC. Acute hemolysis following iodine tincture ingestion. Hum Exp Toxicol. 2011;30(10):1716–9.
27. Hashemnia D, Moaddabi A, Monosi S, Solhani P, Moanma N, Issazadeh M. The efficacy of 1% Betadine mouthwash on the incidence of dry socket after mandibular third molar surgery. J Clin Exp Dent. 2018;10(5):e445–e9.
28. Rahn R, Adamietz IA, Boettcher HD, Schafer V, Reimer K, Fleischer W. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology. 1997;195(Suppl 2):S7–51.
29. Kim JH, Rimmer J, Mard N, Ahmadianzadeh A, Harvey RJ. Betadine has a ciliotoxic effect on ciliated human respiratory cells. J Laryngol Otol. 2015. https://doi.org/10.1017/S0022215114002746.
30. Ramezanpour M, Smith J, Poulis AJ, Wormald PJ, Veugelde S. In vitro safety evaluation of a povidone-iodine solution applied to human nasal epithelial cells. Int Forum Allergy Rhinol. 2020;10(12):1225-75.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.